Clinical Model‐Informed Precision Dosing Consult Service for Accelerating Personalized Medication in Pediatric Patients

Traditional dosing strategies often rely on a "one-size-fits-all" paradigm, assuming an "average" patient with typical demographic and pharmacological characteristics. In reality, this often overlooks existing between-patient variability and can lead to suboptimal drug exposure or toxicity. This issue is especially pronounced in pediatric patients, who experience rapid growth and development of organ functions. Although patient's age and body size are often considered when determining pediatric dose, those factors account for only a relatively small part of the variability. Pharmacometrics provides a rigorous framework for characterizing drug behavior, uncovering patient-specific covariates driving variability, and allows translating insights derived from adults to pediatric populations. Model-informed precision dosing (MIPD) integrates quantitative pharmacological models to leverage clinical data from patients (e.g., drug concentrations and biomarkers) to predict drug exposure and response, thereby informing optimal dosing strategies to maximize clinical benefits. While MIPD has demonstrated feasibility and clinical benefits, it remains underutilized in routine clinical practice. In this article, we describe the establishment and operation of an MIPD consultation service within an academic children's hospital. Through real-world examples, we illustrate how precision dosing workflows can be integrated into routine clinical care and highlight key considerations for further dissemination. By sharing our experience, we aim to bridge a critical gap in the literature and provide a practical blueprint for operationalizing MIPD to advance personalized therapy in pediatrics.